Global Adcetris Insights 2025, Forecast To 2034
7 Mar, 2025
What Has Been the Growth of the Adcetris Market So Far?
The adcetris market has seen considerable growth due to a variety of factors.
• The market size of adcetris has seen a robust escalation over recent years. There's projected increase in its worth from $1,283.57 million in 2024 to $1,398.89 million in 2025, displaying a compound annual growth rate (CAGR) of 9.0%.
This considerable uprise during the historical period can be correlated to the escalating cases of hodgkin lymphoma and ALCL, intensifying knowledge of CD30-positive malignancies, extension of lymphomas treatment avenues, development in health and cancer care infrastructure and adoption in primary and relapsed/refractory treatments.
What Are the Future Growth Projections for the Adcetris Market?
The adcetris market is expected to maintain its strong growth trajectory in upcoming years.
• Predictions indicate a robust increase in the size of the adcetris market over the coming years. The market value is estimated to escalate to $1,954.71 million by the year 2029, recording a compound annual growth rate (CAGR) of 8.7%.
The surge during the predicted period can be linked to the increment in oncology research funding, growing necessity for precision medicine, penetration into emergent markets, hardened emphasis on patient access programs, and ongoing clinical evaluations for wider indications. Key tendencies over the forecast period encapsulate burgeoning adoption of targeted treatments in oncology, diversification into new indications for CD30-positive malignancies, expansion in healthcare expenses and accessibility in emergent markets, progress in antibody-drug conjugate technologies, and ratcheting demand for personalized cancer remedies.
What Are The Core Factors Supporting Growth In The Adcetris Market?
The growth of the adcetris market is anticipated to be driven by the escalating incidence of cancer. This disease category, marked by unchecked proliferation and dissemination of irregular cells within the body, is on the rise. This is attributable to factors such as poor lifestyle habits, which include inadequate diet and insufficient exercise, increased interaction with environmental pollutants, and advancements in diagnostic methodologies. Adcetris offers important advantages to cancer patients as it specifically targets CD30-positive cancer cells, consequently delivering strong cytotoxic agents directly to the tumor location. This enhances the effectiveness of the treatment, minimizes systemic adverse effects, and provides a viable treatment alternative for patients suffering from particular types of Hodgkin lymphoma and other CD30-expressing malignancies. As reported by the American Cancer Society, a US-based not-for-profit cancer advocacy group, in January 2023, cancer instances rose to 1,958,310 in 2023, and cancer-related deaths amounted to 609,820 in the United States. Hence, the increasing incidence of cancer is propelling the adcetris market.
What Are The Major Segments Within The Global Adcetris Market?
The adcetris market covered in this report is segmented –
1) By Type: Powder, Liquid
2) By Indication: Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, Other Indication
3) By Application: Hospital, Drugs Store, Other Applications
Which Trends Are Expected To Transform The Adcetris Market?
The principal trend in the adcetris market revolves around the advancement of enhanced antibody-drug conjugates (ADCs) and optimized drug delivery solutions such as combination therapies. These are specifically designed to increase therapeutic effectiveness, decrease adverse effects, and accurately target cancerous cells. Combination therapies use a cocktail of two or more therapeutic agents, each with a unique mechanism of action, often working together synergistically, to boost efficacy, reduce resistance, and potentially lower side effects as compared to monotherapy. This approach helps in improving the health outcomes of patients. For example, in October 2023, Takeda Pharmaceutical Company Limited, a pharmaceutical organization based in Japan, earned the approval of the European Commission (EC) for their ADCETRIS (brentuximab vedotin) medication. This medicine, combined with doxorubicin, vinblastine, and dacarbazine (AVD), was designed for the treatment of adult patients diagnosed with previously untreated CD30+ Stage III Hodgkin lymphoma. The ADCETRIS medicine is an antibody-drug conjugate that targets CD30, a principal marker of Hodgkin lymphoma. This trial underscored the fact that combining ADCETRIS with AVD significantly raised the modified progression-free survival rates and overall survival rates compared with traditional therapy methods.
Who Are the Key Players In The Adcetris Market?
Major companies operating in the adcetris market include:
• Takeda Pharmaceutical Company Limited
• Seagen Inc.
What Is The Most Dominant Region In The Adcetris Market?
North America was the largest region in the adcetris market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adcetris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.